Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease
Open Access
- 21 May 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 132 (4), 903-918
- https://doi.org/10.1093/brain/awp024
Abstract
Maple syrup urine disease (MSUD) is an inherited disorder of branched-chain amino acid metabolism presenting with life-threatening cerebral oedema and dysmyelination in affected individuals. Treatment requires life-long dietary restriction and monitoring of branched-chain amino acids to avoid brain injury. Despite careful management, children commonly suffer metabolic decompensation in the context of catabolic stress associated with non-specific illness. The mechanisms underlying this decompensation and brain injury are poorly understood. Using recently developed mouse models of classic and intermediate maple syrup urine disease, we assessed biochemical, behavioural and neuropathological changes that occurred during encephalopathy in these mice. Here, we show that rapid brain leucine accumulation displaces other essential amino acids resulting in neurotransmitter depletion and disruption of normal brain growth and development. A novel approach of administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival. Similarly, norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease. Current findings suggest two converging mechanisms of brain injury in maple syrup urine disease including: (i) neurotransmitter deficiencies and growth restriction associated with branched-chain amino acid accumulation and (ii) energy deprivation through Krebs cycle disruption associated with branched-chain ketoacid accumulation. Both classic and intermediate models appear to be useful to study the mechanism of brain injury and potential treatment strategies for maple syrup urine disease. Norleucine should be further tested as a potential treatment to prevent encephalopathy in children with maple syrup urine disease during catabolic stress.Keywords
This publication has 39 references indexed in Scilit:
- Mechanism of age-dependent susceptibility and novel treatment strategy in glutaric acidemia type IJCI Insight, 2007
- Disruption of BCATm in Mice Leads to Increased Energy Expenditure Associated with the Activation of a Futile Protein Turnover CycleCell Metabolism, 2007
- Social outcome in adults with maple syrup urine disease (MSUD)Journal of Inherited Metabolic Disease, 2007
- Effect of Acute Tyrosine Depletion in Using a Branched Chain Amino-Acid Mixture on Dopamine Neurotransmission in the Rat BrainNeuropsychopharmacology, 2005
- Inhibition of brain energy metabolism by the α-keto acids accumulating in maple syrup urine diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2003
- Abnormal dendritic development in maple syrup urine diseasePediatric Neurology, 1992
- Pyruvate Metabolism in the Brain of Young Rats Intoxicated with Organic and Inorganic LeadJournal of Neurochemistry, 1984
- The Effect of Age upon the Entry of Some Amino Acids into the Brain, and their Incorporation into Cerebral ProteinDevelopmental Medicine and Child Neurology, 1978
- THE INFLUENCE OF HIGH PHENYLALANINE AND TYROSINE ON THE CONCENTRATIONS OF ESSENTIAL AMINO ACIDS IN BRAINJournal of Neurochemistry, 1968
- "Maple Syrup Urine Disease"BMJ, 1959